International intellectual property strategies for therapeutic antibodies
- PMID: 22123063
- PMCID: PMC3242846
- DOI: 10.4161/mabs.3.6.17788
International intellectual property strategies for therapeutic antibodies
Abstract
Therapeutic antibodies need international patent protection as their markets expand to include industrialized and emerging countries. Because international intellectual property strategies are frequently complex and costly, applicants require sound information as a basis for decisions regarding the countries in which to pursue patents. While the most important factor is the size of a given market, other factors should also be considered.
Figures
Similar articles
-
Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.Houst J Int Law. 2002;24(2):227-78. Houst J Int Law. 2002. PMID: 16189914 No abstract available.
-
USA-Morocco deal may extend drug patents to 30 years.Lancet. 2003 Dec 6;362(9399):1904. doi: 10.1016/S0140-6736(03)15006-4. Lancet. 2003. PMID: 14672079 No abstract available.
-
International patent law-boon or bane of biotech?Nat Biotechnol. 2005 Jan;23(1):13-5. doi: 10.1038/nbt0105-13. Nat Biotechnol. 2005. PMID: 15637604 No abstract available.
-
[Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].Cad Saude Publica. 2007 Feb;23(2):257-67. doi: 10.1590/s0102-311x2007000200002. Cad Saude Publica. 2007. PMID: 17221075 Review. Portuguese.
-
Intellectual property protection of plant biotechnology inventions.Trends Biotechnol. 2002 Nov;20(11):456-61. doi: 10.1016/s0167-7799(02)02050-4. Trends Biotechnol. 2002. PMID: 12413819 Review.
Cited by
-
Patent and Marketing Exclusivities 101 for Drug Developers.Recent Pat Biotechnol. 2023;17(3):257-270. doi: 10.2174/1872208317666230111105223. Recent Pat Biotechnol. 2023. PMID: 36635930 Free PMC article. Review.
-
Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions.J Biol Chem. 2025 Jun;301(6):110258. doi: 10.1016/j.jbc.2025.110258. Epub 2025 May 21. J Biol Chem. 2025. PMID: 40409544 Free PMC article.
References
-
- In re Hilmer 359 F.2d 859. (CCPA 1966)
-
- Arts. 6 + 7 of the Argentine Patent Act and Argentine Guidelines for Examination of Patent application, Part C, Chapter IV, 2.1.7.
-
- Decision of the European Court of Justice in case C-34/10 of March 10, 2011. Available from: http://curia.europa.eu.
-
- Association for Molecular Pathology v. United States PTO, 2010 US Dist. LEXIS 35,418. (S.D.N.Y. Apr 2, 2010)
MeSH terms
Substances
LinkOut - more resources
Full Text Sources